Literature DB >> 6450334

Lysosomal glycogen storage disease with normal acid maltase.

M J Danon, S J Oh, S DiMauro, J R Manaligod, A Eastwood, S Naidu, L H Schliselfeld.   

Abstract

Two unrelated 16-year-old boys had mental retardation, cardiomegaly, and proximal myopathy. One also had hepatomegaly. Histochemistry and electronmicroscopy of muscle biopsies showed lysosomal glycogen storage resembling acid maltase deficiency. Biochemical studies of skeletal muscle showed increased content of glycogen of normal structure; acid alpha-glucosidase activity in both urine and muscle was normal. Other enzymes of glycogen metabolism were also normal. The cause of this apparently generalized glycogenosis with no demonstrable enzyme defect is unknown.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6450334     DOI: 10.1212/wnl.31.1.51

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  86 in total

1.  Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy.

Authors:  Michael Arad; D Woodrow Benson; Antonio R Perez-Atayde; William J McKenna; Elizabeth A Sparks; Ronald J Kanter; Kate McGarry; J G Seidman; Christine E Seidman
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

2.  Early-onset lysosomal glycogen storage disease with normal acid maltase.

Authors:  R M Dayan; D L Renaud
Journal:  J Inherit Metab Dis       Date:  2001-08       Impact factor: 4.982

3.  [Diagnosis and differential diagnosis of lysosomal glycogen storage disease].

Authors:  D Fischer; S Paus; R Schröder
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

4.  LAMP-2-deficient human B cells exhibit altered MHC class II presentation of exogenous antigens.

Authors:  Victoria L Crotzer; Nicole Glosson; Delu Zhou; Ichizo Nishino; Janice S Blum
Journal:  Immunology       Date:  2010-11       Impact factor: 7.397

5.  LAMP2 microdeletions in patients with Danon disease.

Authors:  Zhao Yang; Birgit H Funke; Linda H Cripe; G Wesley Vick; Debora Mancini-Dinardo; Liana S Peña; Ronald J Kanter; Brenda Wong; Brandy H Westerfield; Jaquelin J Varela; Yuxin Fan; Jeffrey A Towbin; Matteo Vatta
Journal:  Circ Cardiovasc Genet       Date:  2010-02-20

6.  Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor.

Authors:  Shusaku Miyata; Genzou Takemura; Yukinori Kawase; Yiwen Li; Hideshi Okada; Rumi Maruyama; Hiroaki Ushikoshi; Masayasu Esaki; Hiromitsu Kanamori; Longhu Li; Yu Misao; Asaki Tezuka; Teruhiko Toyo-Oka; Shinya Minatoguchi; Takako Fujiwara; Hisayoshi Fujiwara
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

7.  Phenotyping an adult zebrafish lamp2 cardiomyopathy model identifies mTOR inhibition as a candidate therapy.

Authors:  Alexey V Dvornikov; Mingmin Wang; Jingchun Yang; Ping Zhu; Tai Le; Xueying Lin; Hung Cao; Xiaolei Xu
Journal:  J Mol Cell Cardiol       Date:  2019-06-20       Impact factor: 5.000

8.  LAMP-2 deficiency (Danon disease).

Authors:  S Di Mauro; K Tanji; M Hirano
Journal:  Acta Myol       Date:  2007-07

Review 9.  Multiple pathogenetic mechanisms in X linked dilated cardiomyopathy.

Authors:  N Cohen; F Muntoni
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

10.  Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey.

Authors:  P Charron; E Villard; P Sébillon; P Laforêt; T Maisonobe; L Duboscq-Bidot; N Romero; V Drouin-Garraud; T Frébourg; P Richard; B Eymard; M Komajda
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.